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 Pyridoxal phosphate (PLP) dependent enzymes have the ability to manipulate amino acid 
substrates, serving variously as (i) racemases, transaminases, and beta- or gamma eliminases (all 
involving Cα-H bond cleavage); (ii) decarboxylases (Cα-CO2- bond cleavage), or (iii) 
retroaldolases (Cα-Cβ bond cleavage).  Dunathan posited that stereoelectronics govern the key 
C-X bond cleavage step across the class of PLP enzymes; namely by aligning the scissile bond of 
the substrate with the extended pi system of the substrate-PLP imine that bond is weakened.  A 
mechanistic understanding of electron flow in this enzymatic class has motivated many groups, 
including the Berkowitz group, to develop mechanism-based enzyme inactivators for specific 
PLP enzymes.  Most relevant to this thesis is the finding that L-alpha-(2’Z- fluoro)vinyllysine, 
designed as a “suicide substrate” is, indeed, an efficient  irreversible inactivator (t1/2 ~ 3 min, Ki 
~ 100 uM, partition ratio ~ 16) of  lysine decarboxylase from Hafnia alvei (K. R Karukurichi et 
al. J. Am. Chem. Soc. 2007, 129, 258-9)  while the D-antipode is a slow substrate.  
This thesis is motivated by the desire to better understand this interesting result at the 
molecular level.  Described is a streamlined protocol for the purification of this useful model 
enzyme from the native source, Hafnia alvei..  The ultimate goal is prepare homogeneous protein 
of sufficient quality and quantity to permit its successful crystallization to yield diffraction 
quality crystals.  This thesis details and documents an improved purification procedure of LDC, 
as well as presents preliminary data toward its crystallization. The thesis will also review related 
key precedents in the field, both for the successful mechanism based inactivation of PLP-
dependent enzymes, and for the structural inactivation, principally involving with protein 
crystallography 
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I. Background 
 
a) Pyridoxal Phosphate 
 Pyridoxal phosphate (PLP) is the 
active form of Vitamin B61.  PLP serves as 
an essential cofactor for a variety of 
enzymatic processes.2  The beauty of PLP is 
its ability to serve a variety of functions.  
PLP-dependent enzymes generally perform 
chemistry on amino acids, and can cleave bonds to the α-carbon in transamination, 
racemization, decarboxylation, and retroaldolase reactions.1-3  At the β- and γ-positions, 
PLP enzymes have the ability to facilitate eliminations or replacements.3   
 Harmon Dunathan (Haverford College) proposed a now classic model to explain 
how PLP-dependent enzymes are able to use a single cofactor for so many 
transformations, and yet maintain specificity for a particular reaction within a given 
active site.4  He proposed that a given PLP-
enzyme active site is able to dictate which 
bond to the α-carbon  is broken by aligning 
that C-X bond with the extended pi-system 
of the cofactor imine.  The Dunathan 
hypothesis implies that the ensuing 
electron delocalization is able to lower the 
energy of the transition state for bond 
Figure 1.1 Vitamin B6 and PLP  
Figure 1.2 The Dunathan Hypothesis 
(illustrated for a decarboxylase active site) 
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breaking, thereby increasing the rate of the reaction.  This stereoelectronic argument has 
found general acceptance among PLP chemists, although there is some discussion on the 
generality of the concept.4-6 Both computational7,8 and kinetic9,10 studies are also 
consistent with the Dunathan hypothesis.  Figure 1.2 depicts a Cα-CO2- bond aligned with 
the pi-system, as expected for a decarboxylase enzyme.  By rotating around the Cα-N 
bond in 120° intervals, one arrives at the predicted transition state geometries for a 
racemase (Cα-H bond aligned), or a retroaldolase (Cα-Cβ bond aligned).   
 The Dunathan hypothesis is discussed as it proposes that there are certain 
electronic and geometric constraints upon PLP catalysis, and elements of this hypothesis 
are testable by x-ray crystallographic examination of PLP enzymes.  This thesis is 
concerned with the purification of lysine decarboxylase, toward its eventual 
crystallization, by those who will continue on the project.  As will be discussed below, 
identification of an active site proton donor in the vicinity of the cofactor’s pyridine 
nitrogen is a key element in considering the likelihood of complete electron 
delocalization (i.e formation of a quinonoid intermediate) along the PLP enzyme reaction 
coordinate.  Solution of the three dimensional structures of either an internal aldimine or 
(better) an external 
aldimine (e.g. with 
a bound substrate 
analogue or 
inhibitor) allows 
one to better 
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identify such active site residues. 
 On the other hand, the fact that nature has also evolved pyruvamide dependent 
enzymes that are able to catalyze some of the same reactions as PLP-dependent enzymes 
suggests that extended electronic delocalization is not always essential for such 
chemistry.  For example, bacterial histidine decarboxylase converts L-histidine to 
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histamine by utilizing PLP (Gram-negative species) or pyruvamide (Gram-positive 
species)11  For a pyruvamide enzyme, the presumed intermediate upon decarboxylation,  
would delocalize the resultant electron density across three centers and four p-orbitals, as 
opposed to 5 centers and 9 p-orbitals for a fully delocalized PLP-based system.  Table 
1.111-19 depicts a variety of PLP- and pyruvamide-dependent histidine decarboxylases, 
along with their kinetic constants. By analyzing other PLP-only-dependent amino acid 
DC’s, it is seen that kinetic data for histidine DC are not atypical for such enzymes. 
Specifically, aromatic amino acid DC displays kcat values of 188, 122 and112, as 
compared with 52, 92, 107,0.9 and101 for the PLP-dependent histidine DC.  For arginine 
DC, the difference between the PLP-dependent (kcat =18.5 and 704 ) and pyruvamide-
dependent (kcat = 2.65 )  enzymes is larger  suggesting that, perhaps as much as an order 
of magnitude in rate 
enhancement may be 
gained via the increased 
conjugation in PLP vs. 
pyruvamide 20  Other 
kinetic data from other 
PLP-dependent 
AADC’s such as 
ornithine 
decarboxylase21,22 and 
lysine decarboxylase23 
supports this theory, Figure 1.4 WT alanine racemase with alanine phosphonate  
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seeing kcat values ranging from 3.1 to 383 sec-1.  Interestingly, overall it appears that there 
is not a large nor a general correlation between catalytic efficiency and cofactor used 
across the family of AADC enzymes.  This observation increases interest in studying the 
validity and generality of the both the bond alignment and the pi-delocalization tenets of 
the Dunathan hypothesis. 
 Another enzyme that has been widely studied in debate over the Dunathan 
hypothesis is alanine racemase.  According to the crystal structure of alanine racemase, 
there are three essential residues that give insight to the mechanism.  In the conversion of 
L-alanine to D-alanine, tyrosine-265 serves as the essential base to deprotonate the α-
proton on the si-face of bound L-alanine.  This is inferred from the crystal structure of a 
bond phosphono-analogue of L-alanine (pdb 1BD0).  Reprotonation by the active site 
lysine (Lys 39) residue then likely occurs on the re-face, allowing for conversion of L-
alanine to D-alanine (Figure 1.5).  
Toney uses this crystal structure to argue that even in the absence of a quinonoid 
intermediate, a PLP-enzyme is still able to catalyze a racemase reaction at good rates.  
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His argument is based on the presence of arginine-219 near the pyridine nitrogen.  Given 
the generally lower acidity of a guanidium functionality (pKa ~ 12.5 for free Arg) 
compared to a carboxylic acid functionality (pKa~ 3-5 in solution), Toney hypothesizes 
that the formation of a quinonoid intermediate is less likely in this enzyme.  Inspecting 
this structure, I find that the pyridine-N/Arg-219-N distance is measured at 2.93 Å, in 
contrast to 2.6 Å,  for the aspartate oxygen-pyridine nitrogen in the crystal structure of 
ornithine decarboxylase from Lactobacillus (pdb ID 1ORD), hinting that hydrogen 
bonding is still present but there may not be a complete transfer of the proton.  Toney 
utilizes a pKa argument, stating that in solution the arginine has a pKa of 12.6 is unlikely 
to protonate the nitrogen within the pyridine ring with a pKa of 5.  It is well to note that 
active site bases can have dramatically lowered pKa’s in appropriate active sites.   
Perhaps the classic case here is that the active site lysine in acetoacetate decarboxylase, 
estimated by Westheimer and co-workers to be 5.9, based upon active site titration of 2,4-
dinitrophenyl propionate with acetoacetate decarboxylase. 24 
 These initial results gave insight to study the mechanism of alanine racemase.25-28  
Toney mutated the active site arginine to a variety of amino acids to study the effect on 
reaction rates.26  As Table 1.2 depicts, the weaker proton donors have large affects on the 
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rate of reaction, decreasing the catalytic efficiency of the enzyme.  On the other hand, one 
actually observes the quinonoid intermediate for the R219E by UV analysis.  Moreover, 
the R219E mutant had an increased propensity to give transamination.  WT alanine 
racemase favors racemization over transamination 106:1, where R219E alanine racemase 
favors racemization over transamination 185:1.  This suggests that, in general, (N-
protonated) quinonoid intermediates may have a higher propensity for C4’-protonation, 
relative to Cα-protonation, than their non-delocalized aza-allylic anion counterparts.   
Accordingly, Toney has suggested while this may prove to be an example that disfavors 
the production of the quinonoid intermediate, it also suggests that specificity of the 
reaction catalyzed may be dependent on formation of the quinonoid intermediate, or lack 
thereof. 
b) Lysine Decarboxylase 
 Although the three dimensional structure of lysine decarboxylase (LDC) has yet 
to be determined, the structures of numerous PLP-dependent enzymes have been solved 
crystallographically.  Despite the vast functionality of PLP-dependent enzymes, all of 
these can be categorized into one of five fold types29: aspartate amino transferase family 
(Fold Type I), tryptophan synthase family (Fold Type II), alanine racemase family (Fold 
Type III), (D)-alanine aminotransferase family (Fold Type IV), and starch and glycogen 
phosphorylases (Fold Type V).29   
 One of the most interesting of the fold types is Fold Type V, which consists of 
only glycogen phosphorylase and maltodextrin phosphorylase.  These enzymes are 
necessary to break and phosphorylate a glycosyl linkage, with PLP bound to an active 
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site lysine.30  Withers, as well as others, have seen that PLP is necessary for the reaction 
to proceed, however, there is no Schiff base formation as seen in all other PLP-dependent 
mechanisms. 
In order to better understand the mechanism of glycogen phosphorylase, Withers 
developed a series of PLP analogues.31-33  Three mechanisms for glycogen phosphorylase 
have been proposed.  The first mechanism proposes that PLP phosphate could attack the 
C-1 carbon while an active site histidine could serve as a general acid to protonate the 
leaving glycosidic oxygen.31  The second hypothesis is that the phosphate group of the 
PLP serves directly as a general acid to protonate the leaving oxygen.  Evidence has been 
obtained by the Withers group that speaks against the second hypothesis.  Namely, this 
research group was able to replace the cofactor in glycogen phosphorylase with both the 
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phosphonate (pKa(2) ~ 8) and the α,α-difluorinated phosphonate (pKa(2) ~ 5.5) 
analogues of PLP.  Though these are poorer and better Bronsted acids than the native 
PLP-phosphate (pKa(2) ~ 6.5) respectively, only minor changes seen in reaction rate are 
seen.  This in turn suggests that leaving group protonation by cofactor does not occur, at 
least not in the rate determining step. 
The third proposed mechanism that has been suggested is that the PLP  phosphate 
(or phosphonate) group can accept a hydrogen bond with inorganic phosphate (HPO42-) 
which can facilitate transfer of this phosphate group to glycogen, resulting in α-glucose-
1-phosphate, as seen in Scheme 1.1a.31  Studies have shown that PLP functions primarily 
as an essential bridge to facilitate transfer of an inorganic phosphate to the sugar through 
this hydrogen bond.32 
  This interaction was seen utilizing the natural pyridoxal phosphate, as well as 
seeing a comparable rate with the α-difluorinated phosphonate analogue of PLP.31-33 
Interestingly, since the mono-fluorinated phosphonate is also able to facilitate the 
phosphorylation of α-glucose-1-phosphate, it may not be essential to assist in formation 
of the hydrogen bond.  In order to 
test this proposed mechanism, 
Withers and coworkers synthesized 
5’-pyridoxal-1-diphospho-α-D-
glucose (Figure 1.5b, α-PLPPG), 
and its rate of reconstitution was 
compared to the rate of 
10 
 
reconstitution of 5’-pyridoxal-1-phospho-β-D-glucose (β-PLPG).  It was found that the 
α-PLPPG analogue had a rate of reconstitution that was one third less of PLP, yet was 38 
fold better than β-PLPG .31  This difference in rate shows that the pocket of the holozyme 
has space sufficient to hold PLP and an additional phosphate group, though it is unlikely 
that an actual pyrosphosphate linkage actually forms along the reaction coordinate. 
Also, glycogen phosphorylase was found to catalyze cleavage of the alpha-
glucosidic linkage to PLPP, thus releasing glucose-centered oxocarbenium ion-like 
species that ultimately gives glucose and leaves PLPP covalently bound to the enzyme.  
This finding is consistent with glycogen phosphorylase using the PLP as a catalyst by 
hydrogen bonding with inorganic phosphate, thereby facilitating its attack upon a similar 
cationic glucosyl center.  The decrease in rate of reconstitution from the pyrophosphate-
linked cofactor-glucose construct suggests that the two are likely unattached.  Crystal 
structures also are unable to unambiguously confirm/refute this hypothesis,  although 
continued studies along these lines are needed.32,33  Glycogen phosphorylase is a rare case 
where chemistry is created without formation of the Schiff base with the substrate.  
Chemistry occurs with PLP remaining in the form of the internal aldimine.  PLP enzymes 
of the other four fold types, however, appear to perform the three basic functions of 
general PLP-dependent enzymes. 
11 
 
   Fold Type I (Aspartate aminotransferase Family) is the most well studied of all 
PLP-enzyme fold types based on the number of solved crystal structures, and also 
accounts for a majority of the PLP dependent enzymes.29   Members of this fold type are 
found to be active as homo-dimers, in general, with subunits comprising a large domain 
and a small domain.  Out of 18 crystal structures identified for Fold Type I, the position 
of the cofactor bound appears to be nearly identical in all cases, with the PLP attached to 
a lysine side chain in the large domain.29  The Fold Type I family contains many 
enzymes, including those breaking three different bonds to the α-carbon, such as 
aminotransferase subclass 1 and 2 (alpha-C-H), tyrosine-phenol lyase (alpha-C-H), serine 
hydroxymethyltransferase (alpha-C-C(side chain)), bacterial ornithine decarboxylase 
(alpha-C-CO2-), as well as others.29  Because LDC has such a high homology with ODC 
from Lactobacillus sp., having 34% sequence identity and 51% sequence homology over 
Figure 1.6 PLP Dependent Enzyme Fold Types 
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731 amino acids (vide infra), it is inferred that LDC likely exists in the Fold Type I 
family. 
 Schneider had developed a table of crystallized enzymes, but since 2000, over 100 
crystal structures of PLP-dependent enzymes (without substrates, inhibitors, or 
mutations), so his fold type classification was in need of expansion.  Again, the table was 
developed by looking at protein folds seen in the crystal.  Table 1.3 presents my effort to 
establish an up to date version of the Schneider table, taking into account the very 
significant body of structural data that has since been deposited in the pdb.   
Table 1.3 Fold types of PLP-dependent enzymes 
 Enzyme Species Function 
Year 
discovered 
PDB 
Code 
Fold Type I     
 Aspartate Amino Transferase chicken34 Aminotransferase 1982 1AAT 
  E. coli35 Aminotransferase 1994 1ARS 
  Pig36 Aminotransferase 1997 1AJR 
  
Saccharomyces 
cerevisiae37 Aminotransferase 1998 1YAA 
  Thermus Thermophilus 38 Aminotransferase 1998 1BJW 
  Rhodobater sphaeroides39 Transferase 2010 3NRA 
  
Plasmodium 
falciparu(unpublished) Transferase 2010 3K7Y 
  mouse40 Transferase 2010 3PD6 
 Dialkylglycine Decarboxylase Pseudomonas cepacia41 Decarboxylase 1994 1DGD 
 Tyrosine Phenol-Lyase Citrobacter freundii42 Lyase 1997 2TPL 
  
Erwinia 
Herbicola(unpublished) Lyase 2003 1C7G 
 Ornithine Aminotransferase Human43 Aminotransferase 1998 1OAT 
 Aromatic Amino Acid Aminotransferase Paracoccus denitrificans44 Aminotransferase 1998 1AY4 
 Ornithine Decarboxylase L. bacillus45 Decarboxylase 1995 1ORD 
 Glutamate-1-Semialdehyde Aminomutase Synechococcus sp.46 Aminotransferase 1997 2GSA 
 Aromatic Amino Acid Aminotransferase Pyrococcus Horikoshii OT347 Aminotransferase 2001 1DJU 
 Tyrosine Aminotransferase E. coli48 Aminotransferase 1999 3TAT 
  Typanosoma Cruzi49 Aminotransferase 1999 1BW0 
  Human(unpublished) Transferase 2008 3DYD 
  Mouse 50 Transferase 2010 3PDX 
13 
 
 Phosphoserine Aminotransferase 
Bacillus circulans 
(unpublished) Aminotransferase 1998 1BT4 
  E. coli51 Aminotransferase 1998 1BJM 
  Bacillus Alcalophilus52 Aminotransferase 2004 1W23 
  
Yersinia pestic 
CO92(unpublished) Transferase 2011 3QBO 
  
Cytophaga Hutchinsonii 
(unpublished) Transferase 2008 3FFR 
 Cystathionine Beta-Lyase E. coli53 Lyase 1996 1CL1 
  arabidopsis thaliana54 Lyase 2001 1IBJ 
 Cystathionine Gamma-Synthase Nicotiana tabacum55 Lyase 1999 1QGN 
  E. coli56 Lyase 1999 1CS1 
 Serine Hydroxymethyl Transferase Rabbit57 Transferase 1999 1CJ0 
  Human58 Transferase 1999 1BJ4 
  B. stearothermophilus59 Transferase 2002 1KKJ 
 3-amino-5-hydroxybenzoic acid synthase 
Amycolatopsis 
mediterranei60  1999 1B9H 
 
Adenosylmethionine-8-amino-7-
oxonanoate aminotransferase E. coli (unpublished) Aminotransferase 2000 1DTY 
 7,8-diaminopelargonic acid synthase E. coli 61 Transferase 2000 1QJ5 
  
Mycobacterium 
tuberculosis62 Transferase 2008 3BV0 
  Bacillus subtillis62 Transferase 2009 3DOD 
 gamma-aminobutyrate aminotransferase pig
63 Aminotransferase 2004 1GTX 
  E. coli64 Aminotransferase 2004 1SF2 
  
Sulfolobus tokodaii strain 7 
(unpublished) Transferase 2007 2EO5 
 2-amino-3-ketobutyrate CoA ligase E. coli65 Transferase 2001 1FC4 
 2-aminoethylphosphate transaminase Salmonella typhimurium66 Transferase 2002 1M32 
 3,4-dihydroxyphenyl alanine decarboxylase Drosophila67 Lyase 2010 3K40 
 Acetylornithine aminotransferase 
Thermus thermophilus 
hb8(unpublished) Transferase 2005 1VEF 
  
Thermotoga maritime 
(unpublished) Transferase 2007 2ORD 
  
Aquifex aeolicus 
VF5(unpublished) Aminotransferase 2007 2EH6 
 Acyl-CoA Synthase E. coli68 Transferase 1999 1BS0 
 Alanine Aminotransferase 
Pyrococcus 
furiosus(unpublished) Aminotransferase 2004 1XI9 
  Human(unpublished) Transferase 2009 3IHJ 
 Alanine Glyoxylate Aminotransferase Human69 Aminotransferase 2003 1H0C 
  Nostoc sp.70 Aminotransferase 2004 1VJO 
 Alliinase Allium Sativum71 Lyase 2007 2HOR 
 Alpha-aminodipate aminotransferase 
Thermus thermophilus 
hb27 (unpublished) Transferase 2008 2EGY 
 alpha-amino-epsilon-caprolactam racemase Achromobater obae72 Isomerase 2009 3DXV 
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 Arginine Decarboxylase E. coli73 Decarboxylase 2009 2VYC 
 ArnB Transferase Salmonella typhimurium74 Lyase 2002 1MDX 
 Aspartate-Beta-Decarboxylase Pseudomonas dacunhae75 Decarboxylase 2009 3FDD 
 CsdB E. coli76 Lyase 2000 1C0N 
 Cystalysin Treponema denticola77 Transferase 2000 1C7N 
 Cystathionine gamma-Lyase Saccharomyces cerevisiae78 Lyase 2002 1N8P 
  Human79 Lyase 2006 2NMP 
 Cysteine desulfurase E. coli80 Lyase 2003 1P3W 
 DOPA Decarboxylase Pig81 Decarboxylase 2001 1JS6 
 
GDP-4-keto-6-deoxy-D-mannose-3-
dehydratase E. coli82 Transferase 2006 2GMS 
 GDP-perosamine synthase 
Caulobacter crescentus 
cb1583 Transferase 2008 3BN1 
 Glutamate Decarboxylase E. coli84 Decarboxylase 2004 
1PM
M 
 Glutamate oxaloacetate transaminase Human(unpublished) Transferase 2009 3II0 
 Glutamate-1-Semialdehyde Aminomutase 
Thermus thermophilus 
hb8(unpublished) Isomerase 2007 2E7U 
  
Aeropyrum 
pernix(unpublished) Isomerase 2007 2EPJ 
 Glutamine Aminotransferase Thermus thermophilus85 Aminotransferase 2004 1V2D 
 
Glutamine-2-deoxy-scyllo-inosose 
aminotransferase Bacillus circulans86 Transferase 2006 2C7T 
 Glycine Decarboxylase 
Thermus thermophilus 
hb887 Decarboxylase 2005 1WYU 
 Histidinol-phosphate aminotransferase E. coli88 Aminotransferase 2001 1GEW 
  
Corynebacterium 
glutamicum89 Transferase 2008 3CQ4 
 Hydroxykyrnurenine Transaminase Anopheles Gambiae90 Transferase 2006 2CH1 
 Kynureninase Pseudomonas Fluorescens91 Hydrolase 2003 1QZ9 
  Human92 Hydrolase 2004 1W7L 
  Aedes Aegypti93 Aminotransferase 2005 1YIY 
 L-aspartate beta-decarboxylase 
Pseudomonas sp. atcc 
1912194 Decarboxylase 2009 2ZY2 
 L-Cysteine Lyase 
Synechocystis sp. Pcc 
671495 Lyase 2000 1ELQ 
 LL-Diaminopimelate aminotransferase arabidopsis thaliana96 Transferase 2008 3EI5 
 L-methionine alpha-, gamma-lyase 
Pseudomonas putida(not 
published) Lyase 2004 1PG8 
  Citrobacter freundiia97 Lyase 2005 1Y4I 
 L-Threonine Aldolase Thermotoga maritime98 Lyase 2002 1M6S 
 L-Threonine-O-3-Phosphate Decarboxylase Salmonella enteric99 Decarboxylase 2002 1LKC 
 Lysine Aminotransferase 
Mycobacterium 
tuberculosis100 Transferase 2006 2CIN 
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 Methionine Gamma-Lyase 
Trichomonas 
Vaginalis(unpublished) Lyase 2001 1E5E 
 Multiple Substrate Aminotransferase 
Thermococcus profundus(to 
be published) Transferase 2005 1WST 
 N-acetylornithine aminotransferase Salmonella typhimurium101 Transferase 2008 2PB0 
 O-Acetyl homoserine sulfhdrylase 
Thermus thermophilus 
hb8(unpublished) Transferase 2005 2CTZ 
 Ornithine delta-aminotransferase Plasmodium falciparum102 Transferase 2010 3NTJ 
 O-succinylhomoserine sulfhydrylase 
Mycobacterium 
tuberculosis(unpublished) Lyase 2010 3NDN 
 Phenylserine Aldolase 
Pseudomonas 
putida(unpublished) Lyase 2005 1V72 
 Phosphoserine Aminotransferase 
Mycobacterium 
tuberculosis(unpublished) Transferase 2007 2FYF 
  Human(unpublished) Transferase 2008 3E 77 
 PseC aminotransferase Helicobacter pylori 26695103 Transferase 2006 2FNI 
 Selenocysteine Lyase E. coli104 Lyase 2001 1JF9 
  Rattus norvegicus105 Lyase 2010 3A9X 
 Serine Palmitoyltransferase 
Pseudomonas 
paucimobilis106 Transferase 2007 2JG2 
  
Sphingobacterium 
multivorum107 Transferase 2009 3A2B 
 Tryptophanase E. coli108 Lyase 2006 2C44 
 Ureidoglycine-gloxylate aminotransferase 
Bacillus 
subtillis(unpublished) Transferase 2010 3ISL 
 
1-aminocyclopropane-1-carboxylate 
synthase Malus x domestica109 Lyase 2000 1B8G 
 
 
     
Fold Type II     
 Tryptophan Synthase Salmonella typhimurium110 Lyase 1996 1TTP 
 Threonine Deaminase E. coli111 Lyase 1998 1TDJ 
  
Thermus thermophilus 
hb8(unpublished) Lyase 2005 1VE5 
  Salmonella typhimurium112 Lyase 2006 2GN0 
 5,6-aminomutase Clostridium sticklandii113 Isomerase 2004 1XRS 
 
1-aminocyclopropane-1-carboxylate 
deaminase Psuedomonas sp. Acp114 Hydrolase 2004 1TYZ 
 Serine Dehydratase Human114 Lyase 2004 1P5J 
 Serine Racemase S. pombe (unpublished) Isomerase 2005 1V71 
  Rattus norvegicus115 Isomerase 2010 3HMK 
 Threonine Synthase Thermus thermophilus116 Lyase 2003 1UIM 
  E. coli (unpublished) Lyase 2005 1VB3 
  arabidopsis thaliana117 Synthase 2005 2C2B 
  
Mycobacterium 
tuberculosis118 Lyase 2006 2D1F 
      
Fold Type III     
 Alanine Racemase 
Geobacillus 
stearothermophilus119 Isomerase 1997 1SFT 
  Enterococcus faecalis120 Isomerase 2009 3E5P 
  
Mycobacterium 
tuberculosis121 Isomerase 2005 1XFC 
  
Corynebacterium 
glutamicum(unpublished) Isomerase 2007 2DY3 
  
Pseudomonas 
Fluorescens(unpublished) Isomerase 2008 2ODO 
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Oenococcus oeni 
(unpublished) Isomerase 2008 3CO8 
  Bacillus Anthracis 122 Isomerase 2008 2VD8 
  E. coli123 Isomerase 2008 2RJG 
 Ornithine Decarboxylase Mouse124 Decarboxylase 1999 7ODC 
  Trypanosoma Brucei125 Decarboxylase 1999 1QU4 
  Human126 Decarboxylase 2007 2OO0 
 O-Acetylserine Sulfhydrylase Salmonella typhimurium127 Lyase 2000 1OAS 
  
Thermus thermophilus 
hb8(unpublished) Lyase 2005 1VE1 
  arabidopsis thaliana128 Transferase 2005 1Z7W 
  Entamoeba histolytica129 Lyase 2008 3BM5 
 Arginine Decarboxylase 
Paramecium bursaria 
Chlorella virus130 Decarboxylase 2007 2NV9 
  Campylobacter jejuni131 Decarboxylase 2010 3NZP 
 Diaminopimelate Decarboxylase 
Helicobacter 
pylori(unpublished) Decarboxylase 2008 2QGH 
  
Mycobacterium 
tuberculosis132 Lyase 2003 1HKV 
 Cystathionine Beta-Synthase Human133 Lyase 2001 1JBQ 
  Drosophila134 Lyase 2010 3PC2 
 Cysteine Synthase E. coli135 Transferase 2005 2BHS 
  
Mycobacterium 
tuberculosis136 Transferase 2008 3DWI 
 O-phosphoserine sulfhydrylase Aeropyrum pernix K1137 Transferase 2005 1WKV 
      
Fold Type IV     
 D-amino acid aminotransferase L. bacillus138 Aminotransferase 1995 1DAA 
 
Branched-chain Amino Acid 
Aminotransferase E. coli139 Aminotransferase 2001 1I1K 
 4-amino-4-deoxychorismate lyase 
haemophilus somnus 
129py(unpublished) Lyase 2008 3CEB 
  
Thermus thermophilus 
hb8140 Lyase 2008 2ZGI 
 Aminodeoxychorismate Lyase E. coli141 Lyase 2000 1ET0 
      
Fold Type V     
 Glycogen Phosphorylase Oryctolagus cuniculus142 Phosphorylase 1991 1A8I 
 Maltodextrin Phosphorylase E. coli143 Phosphorylase 1997 1AHP 
 
 
 One of the most interesting data points in the table is that ornithine decarboxylase 
is found in both Fold Type I and Fold Type III, depending on whether the prokaryotic 
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form (Fold Type I) or the eukaryotic form (Fold Type III) is under review.  Another 
interesting fact is that certain traits are conserved across different fold types.  As 
expected, all of the enzymes have the cofactor bound by an internal lysine.  Also, the 
internal lysine is always found in an alpha-helix.  This may help explain the observation 
of relatively similar chemistry for a great difference in fold types.  By utilizing these 
similarities and trends seen in fold types, we could predict the fold type of LDC.  
Namely, we would predict Fold Type I for this enzyme, based mostly on the sequence 
similarity to bacterial ornithine decarboxylase. 
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Enzymes were classified by fold type according to a DALI overlay.144  Overlays were 
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done comparing the pdb entry for the enzyme in question to those for established 
members of each fold type: Fold Type I (1AAT – aspartate aminotransferase), Fold Type 
II (1TTP-tryptophan synthase), Fold Type III (1SFT-alanine racemase), Fold Type IV 
enzyme (1DAA-D amino acid transaminase), and Fold Type V enzyme (1A8I –glycogen 
phosphorylase).  Enzymes were characterized by fold type by choosing the pairing that 
gave the highest E value (> 15) and low rmsd score (< 2).  An example of a typical case 
is provided in Table 1.4 for the classification of tyrosine aminotransferase. Figure 1.7 
shows examples of these DALI overlays.  This general method allows for 
characterization of fold type, and thus will likely help provide a menu of appropriate 
reference enzymes to investigators for the construction of homology models.  
Figure 1.8 Decarboxylase Subfamilies 
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 Sandmeier and coworkers separately developed a bioinformatic classification of 
amino acid decarboxylases (AADC’s).145  They took sequences of 54 amino acid 
decarboxylases and performed a sequence alignment.  The sequence alignment found that 
there were four decarboxylase families.  Essentially, each group is separated by sequence 
alignments.  Group I contains a single enzyme, glycine decarboxylase.  Group II contains 
the aromatic AADC’s such as tryptophan DC and tyrosine DC.  Group III contains the 
prokaryotic forms of ornithine, lysine, and arginine DC, which is interesting, because the 
Figure 1.8 Decarboxylase Subfamilies 
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last and final group, Group IV, contains the eukaryotic versions of ornithine and arginine 
DC.145  
 One should take note of the correlation between fold type and decarboxylase 
group.  Groups I, II, and III are all related to Fold Type I, while Group IV is related to the 
Fold Type III family.145  As seen in the sequence alignment of LDC to bacterial ODC 
(Figure 1.9), the two proteins are highly homologous, with 34% sequence identity and 
51% sequence homology from a sequence alignment across approximately 731residues,  
using  Clustal W, on the two proteins.146  Based on the homology to bacterial ODC, LDC 
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from Hafnia alvei can be placed in Group III and, as mentioned, most likely will have a 
Fold Type I structure.  The work described herein builds toward solving that structure. 
Even more importantly, Figure 1.6 shows the importance on the strain of ODC used.  
A second sequence alignment, by comparing LDC (top) with human ODC (bottom), 
shows the distinct differences in homology of LDC with bacterial ODC and human ODC.  
Therefore, based on the high similarities with bacterial ODC, we can continue to make 
the prediction that LDC will display a Type I fold. 
c) Amino Acid Decarboxylases 
 An AADC (Amino Acid Decarboxylase) performs the decarboxylation of an 
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amino acid to form the respective amine.  These enzymes have been found to employ 
either PLP or pyruvamide as a cofactor.1,2,147  For some AA substrates, both types of 
AADC’s are known.  Scheme 1.1, which shows the large spectrum of amino acid targets 
that can be decarboxylated, does not even cover the full substrate range  that AADC’s 
exhibit.  For example, 5-hydroxytryptophan DC is also decarboxylated by Aromatic 
Amino Acid DC and specific PLP-dependent AADC’s are known for arginine, glycine, 
and histidine.  Interestingly, both LDC and Diaminopimelate Decarboxylase (DAP DC) 
have thus far not been found in mammalian sources.2,132  The latter has obvious 
implications from the point of view of antibiotic development.   
 PLP-dependent decarboxylases are believed to proceed through the same basic 
general mechanism: 1) transimination, 2) decarboxylation, 3) α-protonation, and 4) a 
second transimination.2  The first transimination step proceeds by the attack of the amino 
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acid substrate on the internal aldimine (lysine bound) to form the substrate bound 
external aldimine and release the enzymatic lysine.  Next, with the carboxyl group 
aligned with the conjugated pi system, decarboxylation is favored and carbon dioxide is 
released, resulting in formation of a quinonoid intermediate.  This highly conjugated 
intermediate is then protonated at the Cα position.  The final step occurs when the active 
site lysine attacks the external product aldimine, thereby releasing the final product and 
regenerating the internal aldimine.  
d) Inhibition of PLP-dependent decarboxylases  
 There are many useful applications to inhibiting some PLP-dependent AADC’s.  
Two enzymes in particular, Trypanosomal brucei ODC148,149 and (L)-DOPA DC,150 
are the target of inhibitors that serve as useful clinical therapeutics. (DL)-α-
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difluoromethylornithine (DFMO) is an irreversible, mechanism-based inhibitor of 
ODC from Trypanasoma brucei, the parasite responsible for African sleeping sickness 
in humans.151  African sleeping sickness is caused when a human is bitten by an 
infected fly.  Symptoms begin with a painful swollen lesion, and can worsen with 
fever, swelling, anemia, and discomfort.  If untreated, the trypanosomal infection can 
spread to other organs, spinal cord, and the central nervous system.152 DFMO has been 
developed as an intravenously delivered drug. The originally proposed mechanism 
(Scheme 1.3) is based on the interactions of the inhibitor with mouse ODC.149  
Following decarboxylation, DFMO undergoes fluoride expulsion as opposed to α-
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protonation.  Next, an internal cysteine is believed to attack the β-position, via an 
extended conjugation addition mechanism, resulting in the release of fluoride.149  
Reformation of the internal aldimine leads to a covalent modification of cysteine, 
resulting in inactivation.  In 1999, this inactivation mechanism was further supported 
by a crystal structure of the inhibitor bound to the enzyme.148  The crystal structure 
depicted in Figure 1.8 shows the covalently bound adduct. 
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 The second drug discussed is Carbidopa, a drug used in combination therapy for 
the treatment of Parkinson’s disease.150,153  Carbidopa is used in combination with L-
DOPA to cause a dramatic increase of dopamine levels as needed in the substantia nigra 
of the brain for those afflicted with this syndrome.  Dopamine, an active therapeutic for 
Parkinson’s, cannot cross the blood-brain barrier. Carbidopa limits the decarboxylation of 
L-DOPA and allowing it to then cross the blood-brain barrier, where it undergoes 
decarboxylation to dopamine in the brain.  Unlike DFMO, Carbidopa does not become 
covalently attached to the enzyme, but rather forms a tightly bound cofactor hydrazone, 
as seen in the crystal structure.154  As such, Carbidopa might be regarded as an affinity 
reagent, rather than as a mechanism-based inactivator.  These two examples show the 
effectiveness of both affinity reagents and irreversible, mechanism-based inhibitors on 
PLP-dependent enzymes and, also their potential as valuable clinical therapeutic agents.  
These examples have inspired our lab to develop new motifs for the mechanism-based 
inactivation of AADC’s. 
e) Inactivation using vinyl amino acids  
 Though well established in Europe,155 Vigabatrin is a relative newcomer to the 
United States.  Vigabatrin, the  γ-vinylated analogue of γ-amino butyric acid (GABA), 
reduces GABA transaminase activity.  By increasing basal levels of the inhibitory 
neurotransmitter, GABA, Vigabatrin mediates against epileptic seizures.156  Because of 
the added conjugation from the vinyl substituent, the usual quinonoid intermediate can 
undergo protonation at either Cγ- or the C4'- carbon.  Whereas the former pathway can 
lead to inactivation via Michael addition, the latter might lead to adduction via a Mannich 
condensation (“Meztler enamine mechanism”).157  Scheme 1.4 illustrates both possible 
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mechanisms.  The structure of an inhibited enzyme suggested that inactivation proceeds 
via conjugate addition of the active site lysine, following azallylic isomerization, as seen 
in molecular detail in the E-I structure.  This study gives us insight to the potential 
mechanism by which an α-vinyl amino acid might inactivate a decarboxylase enzyme.  
 Investigations by Silverman and coworkers suggest that fluorinating the inhibitor 
slightly modifies the mechanism of inhibition.158  While the same basic routes involving 
C4' or Cγ inhibition are still available, the  mechanistic possibilities are altered.  Instead of 
stopping immediately after nucleophilic addition of the active site lysine into the vinyl 
group during the C4' protonation step, (2'-fluoro)vinyl-GABA is thought to go one step 
further than the non-fluorinated inhibitor by releasing fluoride after the conjugate 
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addition.  Interestingly, no significant difference was observed in effectiveness of 
inhibition between the E or Z fluoro alkene used, although the mechanism of inactivation 
was altered, due to the ability for fluoride to be utilized as a leaving group.159   The 
Silverman studies on florovinyl inhibitors served as some of the key motivations behind 
the design of “quaternary”, α-(2'-fluoro)vinyl AA’s in the Berkowitz lab.160  The 
quaternary amino acids are expected to be inert to PLP-enzymes that require α-
deprotonation, such as GABA transaminase, but may act as covalent inactivators of 
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AADC enzymes, if decarboxylated in such active sites.  
f)  Conclusions 
 Understanding the mechanism of action of an enzyme permits the design, 
synthesis, and evaluation of mechanism-based inhibitors.  Based on the generalities of 
PLP-dependent enzymes155, a viable new “trigger” for the inhibition of LDC was 
developed.  This approach was inspired by examples such as DFMO and γ-(2'-
fluoro)vinyl-GABA, for both of which latent electrophiles are unveiled in the target PLP-
enzyme active sites, ODC and GABA transaminase, respectively, resulting in inactivation 
of these target enzymes.161 
 After successful synthesis of the L-α-(2'Z-fluoro)vinyllysine (FVL) by 
Karukurichi and de la Salud Bea,23,162 inhibition of H. alvei LDC was found to be 
irreversible.  On the other hand, the D-antipode functioned as a slow substrate.  These 
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provocative results within a new AADC inactivation 
motif motivated the research described in this M.S. 
thesis.  It became a central goal to obtain high titres (i.e. 
multi milligram) of homogeneous H. alvei LDC  so that 
this model AADC enzyme might be crystallized and its 
structure determined for the first time.  In principle, this could then lead to the 
interrogation of covalent LDC inactivation by X-ray crystallography, as well. 
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II. Purification of LDC 
a) Previous Purification method 
 In order to attempt enzyme crystallization, LDC must first be purified.  Since 
previous attempts to clone LDC from Hafnia Alvei (H. Alvei) have proven ineffective163, 
isolation of the native protein was pursued.  Attempts at purification of LDC have been 
seen164,165, so the process of purification has been built upon a foundation of previous 
purification reports. 
 Bacterial LDC can be found in a variety of strains including: H. alvei, E. coli, and 
Vibrio parahaemolyticus.  Out of all three bacteria, H. alvei produces the greatest amount 
of LDC, compromising 4% of the total soluble protein.164  For this reason, our lab, as 
well as others has chosen to isolate LDC from H. alvei.  The first published protein 
purification of LDC, from Soda and coworkers,164  employed  Bacterium cadaveris (also 
known as H. alvei - strain IFO 3731), grown up in a controlled medium (L-lysine, 
glycerol, peptone, ammonium sulfate, potassium phosphate, magnesium sulfate, and 
yeast extract).  Cells were broken open by sonication in the presence of protease 
inhibitors and PLP.  Following a heat treatment step (50 °C), ammonium sulfate cuts 
were made, with the first cut having 30% ammonium sulfate saturation and the second 
cut with 55% saturation.  Once the pellet was re-suspended in buffer, it was loaded on an 
ion exchange DEAE-Sephadex column.  The fifth step was a phenyl sepharose column, 
followed by a second DEAE-Sephadex column.   The final step to isolate the protein was 
said to be performed by “crystallization,” obtaining small yellow rod-like crystals that 
were not tested with an x-ray, with a final purification factor of 61 and a yield of 5.9%, 
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with a final specific activity of 86 U/mg.  This laborious procedure and modest yield 
motivated our lab to seek a streamlined purification procedure. 
 Berlin and coworkers, the first group to publish a sequence for LDC from H. 
alvei, employed a different purification, which also involved  size exclusion and an ion 
exchange chromatography, and which provided LDC with a supposedly higher specific 
activity of 110 U/mg, but the difference may reflect experimental uncertainty or 
variation.163,165  The surprising finding in Berlin’s purification was that this specific 
activity resulted from a protein that displayed two bands (88 and 66 kDa) on an SDS-
denaturing gel. 
 In our own lab, Karukurichi developed his own purification method for LDC, 
which involved sonicating crude cells, a 60%  saturated ammonium sulfate precipitation, 
phenyl sepharose chromatography, ion exchange (DEAE Sephadex), and finally size 
exclusion (S-300) chromatography.23  My research investigated a modified version of this 
basic procedure, as described below. 
 
b) Activity Assay 
 To measure the activity of LDC, de la Salud-Bea and Karukurichi adapted the 
previously published Lenhoff assay.23,162  The Lenhoff  assay measures the turnover or 
lysine to cadavarine by spectroscopically measuring the amount of cadaverine reacting 
with picryl sulfonic acid (TNBS).166  The assay works by allowing the enzyme to actively 
convert L-lysine to cadaverine in the presence of lysine (8 mM) for a set time.  After the 
time has passed, enzyme activity is quenched with base and heat.  The quenched solution 
is then heated (47 °C for 7 minutes).  After cooling, TNBS is added to each solution, and 
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the reaction is again heated (47 °C for 7 minutes).  This allows for nucleophilic aromatic 
substitution to occur, covalently attaching cadaverine to the aromatic ring, and 
presumable releasing sulfite.  Interestingly, lysine in solution will not react with TNBS, 
presumably because the amine becomes basic in cadavarine.  Lastly, the derivatized 
cadaverine is extracted with toluene and its absorbance was measured at 340 nm. The 
absorbance measured is then compared to that obtained for a set of standards.  For more 
information, please refer to the experimental section.  
 
c) Protein determination 
 From the published sequence of LDC from H. alvei, the molecular weight of LDC 
appeared to be 82 kDa (or 82,000 g/mol).  Utilizing the Lowry method167, we were able 
to compare absorbance against a common standard, Bovine Serum Albumin (BSA), 
which has a monomeric molecular weight of 66 kDa.  The Lowry method works in two 
steps: 1) Reductino of Cu2+ to Cu+1, and 2) Reduction of the Folin reagent.167  The first 
step proceeds via a Biuret reaction, where copper is complexed with with amide bonds of 
the protein, specifically with aromatic amino acids.167  Potassium hydroxide, CuSO4, 
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sodium carbonate, sodium tartrate, and sodium dodecylsulfate are added to the protein 
mixture, oxidizing peptide bonds to convert Cu2+ to Cu+.167  The second step involves the 
Folin-Ciocalteu reagent being reduced by the copper complex, and the mixtures changes 
from a light purple color to a deep blue color, depending on the concentration of protein 
in solution, which is measured at 650 nm.  A stronger absorbance is related to higher 
protein concentration.  After setting a calibration curve with BSA weight standards, LDC 
protein concentration could easily be estimated.   
d) Protein purification 
 With assays for activity and protein concentration in hand, we next set out to 
optimize LDC purification from the native source.   Cells were grown in a lysine-
supplemented medium (5 g bactopeptone, 5 g yeast extract, 1 g MgSO4•7H2O, 3 g of L-
lysine monohydrochloride per 1 L of solution), and disrupted via sonication in the 
presence of protease inhibitors.    The crude extract was then centrifuged and to the 
supernatant was added a 60% ammonium sulfate saturation.  Although ammonium sulfate 
is generally used in two separate cuts for an increase in purification, preliminary attempts 
to improve specific activity in this manner showed little benefit.  Instead, the ammonium 
sulfate precipitation served as an excellent means for storage, with no activity loss 
detected for up to a year or more of storage.  This method is a simpler means of storage 
as compared to glycerol stocks, because instead of having to use dialysis to remove 
glycerol, the resuspended pellet can be immediately loaded onto the next column.  The 
high ammonium sulfate concentration precipitate insures retention of nearly all LDC 
activity in the stored precipitate.  
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 The first column used was a phenyl sepharose column.  Phenyl sepharose is a 
hydrophobic stationary phase that separates based on hydrophobicity.   Elution was 
performed by using a linear gradient from high (100 mM) to low (10mM) concentration 
of phosphate buffer (with  15 µM PLP at pH 7.0).  By decreasing phosphate 
concentration, and hence decreasing ionic strength, one effects the elutions of proteins as 
a function of increasing hydrophobicity, with the most hydrophobic eluting last.  An 
elution plot is shown in Figure 2.1.  Fractions displaying high absorbance at 280 nm and 
some absorbance at 420 nm were further tested for activity using the Lenhoff Assay, as 
described before.  The fractions collected in Figure 2.1 led to an purification factor of 2.5 
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(seen in Table 2.1a), but in pooling fewer fractions (i.e. two fractions versus the 8 seen in 
Figure 2.1) the purification factor was optimized to 12 (Tabel 2.1b), with a yield of 
38.9%..  The fractions collected had the highest specific activity as determined by the 
Lenhoff and Lowry assays, as described above.  Table 2.1b represents the fully optimized 
purification table in the purification of lysine decarboxylase. 
 Active fractions from the phenyl sepharose column were taken on to the next step.  
While Karukurichi previously used DEAE-Sephadex as an anion exchange column, this 
resin was found to swell dramatically, and yield poor separation.23  Initially, a more basic 
quaternary anion exchange column, Q-Sepharose, was used, with very good results in 
separation of the protein.  This resin showed less dramatic swelling and led to more 
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effective protein fractionation.  However, the purification achieved via phenyl sepharose 
was so significant that it seemed unnecessary to use the Q-sepharose step.  Therefore, this 
column was eliminated, and the active fractions were loaded onto an S-300 size exclusion 
column.  This final column simply separates based on size.  Larger macromolecules 
rapidly traverse the column, while proteins in the size regime of the pores are partially 
retained, and elute more slowly.  Using this streamlined protocol, homogeneous LDC 
was obtained in 13% overall yield with a final specific activity of 91 U/mg.  These results 
were consistent with previously published data from Karukurichi’s  
protein purification.23
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e) The Next Step: Effectiveness of Mass Spectroscopy and Crystallography 
 Both mass spectrometry and crystallography have been used as effective methods 
for the analysis of enzyme sequencing as well as understanding the mechanism of 
inhibition of certain enzymes.63,168 In some instances, mass spectrometry has proved 
more efficient than crystallization, and vice versa.  The methods may be viewed as 
complementary.  Mass spectrometry has the advantage of allowing one to more easily 
examine multiple parallel covalent inactivation mechanisms, because homogeneous 
crystals are not needed.  Moreover, differential sites of alkylation can be examined a 
single “bottom-up” analysis.  The price one pays for this is the need to establish 
significant sequence coverage, which often requires the use of multiple digestion 
enzymes, and which becomes more difficult with larger enzymes.  The “bottom-up” MS 
method has the disadvantage of likely missing non-covalent inactivation mechanisms 
(e.g. Carbidopa) or covalent inactivation mechanisms that can lead to release of inhibitor 
upon workup (e.g. Metzler enamine mechanism169,170 – release of the “Schnackerz 
intermediate”171,172 under basic conditions. 
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Crystallography, on the other hand, is able to give the complete sequence of the 
enzyme in its entirety, showing all contributing residues to the active site, without any 
digestion.  Moreover, non-covalently bound inactivators (e.g. CarbiDOPA) are easily 
seen by this method.  However, crystallizing a protein can be time consuming in the 
attempts to optimize conditions, as well as in learning to growing crystals of a size and 
quality to give an acceptable X-ray diffraction pattern.  It is worthy to note that this may 
soon change with the advent of “free electron laser”-based crystallography. 173,174 
Ideally, our lab would try to crystallize LDC to obtain absolute certainty of the 
enzyme’s structure, and would then use crystallography or mass spectrometry to identify 
the mechanism of inactivation from α-L-(2'-Z-fluoro) vinyllysine on LDC.  Studies as 
shown by Silverman below help to see the importance of both methods in identifying 
mechanisms of inactivation. 168,175 
 (S)-4-Amino-4,5-dihydro-2-thiophenecarboxylic acid is an effective 
inhibitor of GABA-AT.176  Silverman was able to discover a unique means of inhibition 
by using electrospray mass spectrometry and tandem mass spectrometry alone to identify 
the probable mechanism(s).  Out of three mechanisms proposed, all three created 
different adducts: 1) an external aldimine that results from aromatization of the product, 
2) an enamine type 
mechanism, and 3) a Michael 
addition.  All three create 
inactive forms of PLP that will 
slowly be removed from 
within the active site.  If a 
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mechanism is proposed and a molecular mass is known, mass spectrometry can help to 
validate these proposals.  The three candidate structures for the inactive forms of PLP all 
vary substantially in molecular weight. Isolating the modified cofactor product and 
submitting it to tandem MS/MS allowed for the molecular mass of product 1 to be the 
primary candidate, leading their group to conclude that the mechanism of inactivation 
proceeds via aromatization of the adduct. 
 Crystallization offers another means to discovering the path of inactivation.  Next 
to LDC, ODC from Lactobacillus is the most highly homologous PLP enzyme known to 
date.  Fortunately, the crystal structure of ODC has been solved by Hackert177; who found 
that ODC existed in the crystalline form as a hexamer of dimers, or a total dodecamer.  
While the dimer structure seems to fit the fold type 1 of generalized PLP-dependent 
enzymes29, the dodecamer is out of the ordinary.  It is possible that LDC could crystallize 
in a similar manner to ODC based on the high homology, or could behave similarly to 
other fold type 1 proteins.   
 The beauty of crystallography it that is allows for absolute certainty in identity of 
each individual amino acid, as well as seeing the identity of the protein as a whole, rather 
than in fragments as would be seen in mass spectrometry.  This would allow the entire 
quarternary structure of LDC to be fully exposed in its entirety.  Obtaining a successful 
crystal structure would be beneficial in order to have full understanding of the active site, 
PLP’s binding, as well as potential inhibitor interactions. 
 
f) Silverman’s Case of Mechanistic Enzymology by Crystallography 
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 Dr. Richard Silverman has employed isotope labeling, mass spectrometry, and 
crystallography in attempts at depicting mechanistic insights to inactivation of 
enzymes.175  While all three give insightful hints into the possible mechanism of 
inactivation, only crystallization gives scientists a finite structure.  Instead of noting 
radioactivity in the solution or bound to the enzyme, or instead of being given a mass of a 
fragment, an absolute structure is able to be deciphered.  In specific cases, this can 
finalize the inhibited product, thus giving concrete information regarding mechanism. 
 Silverman et. al show an extremely useful example to portray the usefulness of 
mechanistic crystallography.  In the case of GABA-AT, the inhibitor (1R, 3S, 4S)-3-
amnio-4-fluorocyclopentane was developed based on analogy to the structure of 
GABA.168  Studies of activity proved this inhibitor to irreversibly inhibit GABA-AT.  
Because GABA-AT is a PLP- dependent enzyme, both Michael addition or Metzler 
enamine formation are viable products, as seen in Scheme 3.1.  Initially, the mechanism 
of GABA-AT was proposed to proceed via Michael addition based on the fact that 
aminotransferases begin with C4' protonation being a necessary step, as well as other 
inhibitors, like fluoro vinyl GABA proceed via Michael addition, but experiments for this 
inhibitor had not been studied.  Both mechanisms start in the same fashion.  Addition of 
the substrate generates the external aldimine, which undergoes deprotonation of the α-
proton to form the quininoid intermediate, followed by fluoride expulsion.  In the 
Michael addition, the active site Lys will attack the γ-position of the unsaturated iminium, 
which regenerates the quininoid intermediate and results finally in C4' protonation.  Via 
the Metzler enamine addition, the active site Lys generates the internal aldimine releasing 
the small molecule enamine.  This enamine is a good nucleophile and is proposed to  
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attack the C4' carbon, resulting in the final adduct. Interestingly, both mechanisms result 
in fluoride expulsion, thereby eliminating radioactive assays as a means of distinguishing 
the two.  Similarly, if the Metzler enamine does indeed result of an addition of the small 
molecule back into PLP for formation of the final adduct, both mechanisms would give 
products of identical molecular weight.  
  Silverman was not only able to successfully identify the mechanism of 
inactivation of GABA-AT, but was able to use crystallography to visualize the active site 
and see interacting active site residues.168  Arg 192 is able to stabilize the carboxylic acid 
within the inhibitor.  Lys 329 serves as the active site lysine that is able to form the 
internal aldimine.  From these results, Michael addition is conclusively eliminated from a 
possible mechanism of inactivation.  Formation of the adduct seen gives adequate 
information for scientists to hypothesize that the method of inactivation of GABA-AT 
proceeds via the Metzler enamine pathway. 
g) Possible Inactivation Pathways of LDC with the New Trigger 
 
 
  Based on Silverman’s findings, it was essential that we analyze the 
potential paths of inactivation for LDC.  PLP-based enzymes proceed through three 
major pathways: α- protonation, which results in normal turnover, and two possible 
pathways that could result in inactivation: C4' protonation, or Cγ protonation.  Another 
possible method of inactivation, though highly unlikely, is addition directly into the 
quninonoid intermediate. Indeed, careful consideration of the possibilities suggests that 
there could be more than one means of inactivation is possible based on C4' protonation, 
or Cγ protonation.  Because of previous findings within our own lab from Karukurichi 
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and de la Salud-Bea, we know that the  fluoride expulsion accompanies inactivation.23,162  
Of the three most likely inactivation mechanisms, two (nucleophilic Metzler enamine 
mechanism and the electrophilic conjugate addition mechanism) follow from Cγ 
protonation, followed by enamine formation/release.157,178  The third possible mechanism 
was a conjugate addition/elimination following C4' protonation.  Scheme 2.3 depicts these 
three potential inactivation routes.   
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h) Crystallization attempts 
 
 Based on Silverman’s findings, our group seeks to obtain a crystal structure of 
LDC.  This effort is collaborative with Professor Mark Wilson (UNL Biochemistry 
Department).  Previous attempts by Karukurichi in our lab led to the successful 
crystallization of LDC, but the crystals were of insufficient size for diffraction 
experiments.  Here, preliminary crystallization was performed using 10 mM phosphate 
buffer pH 7.0, 15µM PLP, and 15mg/mL LDC, with no positive results.  In the second 
attempt, the buffer was changed to 10 mM malonate buffer pH 7.0, 15µM PLP, 25 
mg/mL LDC, and received two positive hits using the Hampton Screening Kits I and II. 
After proper growth conditions were developed (in lab notebook), crystals were 
obtained, as pictured in Figure 2.6.  This data suggests that crystallization of LDC is 
indeed possible.  
 
i)  Conclusions 
 As results have shown, LDC was successfully purified from the native source, in 
moderate to good yields, with acceptable specific activity.  Modifications have been 
made to the original protocol to eliminate one unnecessary step in purification.  From the 
original purification as published by Soda with seven total steps, the final purification has 
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been reduced to only four steps, with an increased purification factor, initially at 61 and 
improved to 79.  The more streamlined protocol also provides for an improved yield 
(13%) over Soda’s method (5.9%)164 
We have a developed a protocol efficient for production of LDC from H. Alvei.  
LDC isolation is now streamlined, and future efforts in the group will be directed toward 
finding suitable conditions for its effective crystallization.  There are numerous benefits 
to obtaining a crystal structure.  First, a crystal structure would provide the absolute 
sequence of the protein, which would be a valuable piece of information.  This is 
particularly so, given Berlin’s unsuccessful attempts at cloning the enzyme, suggesting a 
possible problem with the sequence.  The crystal structure would help to resolve several 
such outstanding questions about the protein.  Next, obtaining a crystal structure would 
give us the oligomeric state of LDC in crystalline form.  We predict to see a homo-dimer 
structure, but it could have some variance, as seen in ODC from L. bacillus.    
 If the holozyme is able to be crystallized, there is also potential for inhibitors or 
substrates to be crystallized as well.  Within our own lab, α-D-(2'-Z-fluoro) vinyllysine 
was found to be a substrate with slow turnover, so there is a possibility that a crystal 
structure could be obtained with the substrate in the active site.  This could potentially 
provide some insight to the Dunathan hypothesis, if the alignment of the Cα-CO2- is seen 
to be aligned with the extended pi system.  The second target that was synthesized within 
our lab, α-L-(2'-Z-fluoro) vinyllysine, was found to be an irreversible inhibitor of the 
enzyme.  If we were able to crystallize the inactivated protein with the processed 
inhibitor bound, similarly to DFMO in ODC and vinyl-GABA in GABA transaminase, 
the crystal structure would give useful insight to the mechanism of inactivation.  
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Alternatively, it may be possible to diffuse such a suicide substrate into the crystal of the 
holoenzyme, provided that the motion associated with the transamination and inactivation 
chemistry would not significantly disrupt the crystals. 
   Currently, a successful and improved purification has been presented, with 
preliminary results showing that crystallization is an obtainable goal.  With our lab’s new 
purification protocol, crystallization of LDC is within our grasp. 
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III. Experimental 
Hafnia alvei was grown from a purified sample from K. Karukurichi, which was grown 
from Hafnia Alvei strain IFO 3731 was bought from the Institute for Fermentation of 
Osaka.  Centrifugation was completed using the SorvallRC5B.  Protein concentration was 
measured using the Lowry assay.  Protein activity was measured using the Lenhoff assay. 
 
Purification of Lysine Decarboxylase: 
 H. Alvei was grown a modified Laemmli broth, consisting of 5 g bactopetpone, 5 
g yeast extract, 1g MgSO4•7H2O, and 3 g of L-lysine monohyrdide per 1 L of solution.  
Initially, the bacteria was grown in a starter culture consisting of 50 mL of the culture 
broth, and after 12 hours at 43 °C was split into six 4 L flasks, containing 2 L of broth.  
The solution was kept in a shaker for 3 days at 150 rpm and 43 °C.   
 To 24 g of wet cells, ethylenediaminetetraacetic acid (EDTA), 
phenylmethanesulfonyl fluoride (PMSF), and 80 mL of 10mM potassium phosphate 
buffer (Buffer A), and 6 crushed capillary tubes were added to increase surface area, and 
separated into two 250 mL beakers.  The beakers were sonicated on ice five times in 
thirty second intervals, and was centrifuged at 10,000 rpm for 15 minutes.  The 
supernatant was decanted, and a 500 µL fraction was taken for analysis.   
 To the remaining liquid, 60% ammonium sulfate saturation was added at 4 °C and 
was stirred for 20 minutes until completely dissolved.  The mixture was spun at 10,000 
rpm for 15 minutes.  Nearly all activity (99%) was found in the pellet.  The supernatant 
was discarded and the pellet was stored at -70 °C. 
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 The pellet was resuspended in 80 mL of 100 mM potassium phosphate pH 6.0 
(Buffer B), and was centrifuged at 15,000 rpm for 15 minutes.  The supernatant was 
decanted and was concentrated down to 60 mL.  The solution was loaded onto a 200 mL 
phenyl sepharose column and eluted with a gradiant of 100 mM (250 mL) to 10 mM (250 
mL) potassium phosphate buffer, pH 6.0.  These fractions were collected in 5.5 mL 
increments.  To find active protein, 300 µL of each fraction was placed on a 96-well plate 
and measured the absorbance at both 280 nm and 420 nm.  The fractions were then tested  
by the Lenhoff assay, which will be described later. 
 Active fractions from the phenyl sepharose column were concentrated to 2 mL 
and were loaded onto the S-300 column, and was eluted using 10 mM potassium 
phosphate buffer with 10 µM PLP, and were collected in 5.5 mL fractions.  Active 
fractions were measured by the Lenhoff Assay. 
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Activity Measurements 
 
Cadavarine Standard 
 A 2.1 mM solution of cadaverine stock solution was made.  9.5 µL to 95 µL of 
the cadaverine solution was added to 24 µL of 100 mM L-lysine.  The solution was 
finalized to 300 µL by adding 10 mM phosphate buffer, and the tube was heated at 43°C 
for 7 minutes.  Once brought back to room temperature, 300 µL of 22 mM TNBS was 
added and the solution was heated at 43 °C for 7 minutes.  Once cooled to room 
temperature, 600 µL of toluene was added, and the solution was mixed on a mini vortex 2 
times for one minute.  300 µL of the organic layer was extracted and the absorbance was 
 
Volume 
(mL) 
Total 
Units 
Units/mL 
Total 
Protein 
(mg) 
Lowry 
Assay 
Specific 
Activty 
(U/mg) 
% 
Yield 
Purification 
Factor 
Crude 50 2874 57 2499 1.15 100 1 
Ammonium 
Sulfate 
27 2833 104 2380 1.19 98.6 1.03 
Phenyl 
Sepharose 
4.5 1118 248 81 13.8 62.1 12 
S-300 1 382 382 4.2 91 13 79 
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measured at 340 nm for a range of concentrations of cadaverine.  Absorbance versus 
concentration was plotted, and the slope gave the absorbance per 1 µM of cadaverine. 
 
Activity of LDC 
 Each test tube contained 20 µL of selected LDC and 256 µL of 10 mM phosphate 
buffer pH 7.0.  At time point 0 minutes, 24 µL of a 100 mM L-lysine solution was added 
to the test tube. At the timepoint in which the reaction was desired to be stopped, 300 µL 
of 1.0 M K2CO3 was added to quench the reaction, and the mixture was heated at 43 °C 
for 7 minutes.  After the solution was allowed to cool to room temperature, 300 µL of 22 
mM TNBS was added and heated again at 43 °C for 7 minutes.  Once the second solution 
was cooled to room temperature, 600 µL of toluene was added to the solution.  The 
mixture was agitated in the mini vortex two times, each lasting for one minute.  The final 
product resulted in two layers, an orange aqueous layer and a clear to yellow organic 
layer.  Interestingly, measurements of the crude extract also have a frothy bright yellow 
substance at the top of the aqueous layer.   
 After completing the reaction, a 300 µL aliquot of the toluene layer was placed in 
the quartz plate and absorbance was measured at 340 nm.  A graph plotting absorbance 
vs. time was made, with the slope being used to calculate activity.  Based on the 
calibration curve, we can calculate the activity units in the 300 µL solution.   
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Protein Measurements 
 For the Lowry Assay, the following solutions can be made ahead of time and used 
for multiple assays: 
 Solution A: 0.5 g CuSO4, 1.0g sodium citrate, and 100 mL dd H2O 
 Solution B: 20 g Na2CO3, 4g NaOH, and 1L dd H2O 
When the assay will be run, the following solutions should be made fresh: 
 Solution C: 100 mL Reagent B 
 Solution D: 10 mL Folin-Ciocalteau reagent (SIGMA, 2 N) and 10 mL H2O 
The standard protocol was followed: 
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1.  10 BSA standards were made in triplicate ranging from 0.1 mg/mL BSA to 
 1 mg/mL BSA, in increments of 0.1 mg/mL 
2. 1.25 mL of solution C and 250 µL of the standard or the protein to be  
 measured were mixed, vortexed at a medium speed, and were let to sit in  an 
incubator at 37 °C for 10 minutes. 
3. 125 µL of Solution D were added to the solution, vortexed at a medium  speed, 
and incubated at 37 °C for 25 minutes. 
4. Absorbance of the solutions was measured at 650 nm.   
A plot of the standard absorbance versus concentration was made, with the slope of the 
plot giving the Abs/mg of protein.  The absorbance of the purified protein could also be 
used to estimate the amount of protein present in solution. 
 
 
Ammonium Sulfate Test 
 A test was run to compare the activity of Karukurichi’s ammonium sulfate 
precipitant which had been stored at -80 °C for two years versus a freshly made 
ammonium sulfate precipitation.   A small fraction of each pellet was re-suspended in 1 
mL of 10 mM phosphate buffer pH 7.0 in the presence of 15 µM PLP.  20 µL aliquots 
were taken from both samples, and a Lenhoff activity assay was run on the two samples.  
Interestingly, the old sample appeared to have slightly higher amounts of activity than the 
new pellet, with the activities differing slightly.  This shows that even after years of 
storage, ammonium sulfate pellets serve as a suitable storage method. 
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Native State Determination 
 
Native state determination of LDC was determined by running LDC on a 4% stacking, 
9% resolving discontinuous polyacrylamide gel.  The gel was run at a constant current of 
40 mA and was cooled using flow cooling as set by the Hoeffer Mighty Small II 
electrophoresis apparatus.  BSA was used as a standard.  From the gel, it appears that 
LDC exists as a monomer or a dimer, based on molecular weight measurements. 
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Sedimentation Equilibrium Experiment 
 An ultracentrifugation was run to perform a sedimentation equilibrium 
experiment.  If LDC existed as a dimer, the Beckman-Coullter Proteomelab XLI Protein 
Characterization system was run at 8000 rpm with a protein concentration of 0.4 mg mL-1 
in a buffer of 10 mM potassium phosphate pH 6.0 at 20 °C for 24 hours, and was run at 
11000 rpm under the same conditions to test for a monomer at molecular weight 83 kDa.  
Data was collected using Micocal Origin software with the Beckman ultracentrifuge data 
analysis add-ons.  The data was analyzed at 280 nm.  After analysis, and given a 95% 
confidence interval, the molecular weight from both runs was shown to be 398 (±22) kDa 
based on its sequence.  The molecular weight suggests LDC existing in a pentameric 
state, which would correlate to work done by Beier, showing a molecular weight of 422 
kDa.    
 An issue regarding these results is that they do not agree with the results obtained 
from the gel filtration, however, it may be that LDC is exists as an equilibrium mixture of 
several different oligomeric forms.  In a simple analysis here, one could have equal 
amounts of tetramer and hexamer, giving an apparent averaged molecular weight of a 
pentamer. 
 
Crystallization of LDC 
 
1st screening: 
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LDC in a 30% glycerol stock was loaded onto a G-25 column and was eluted with 10 
mM potassium phosphate buffer pH 6.0 in 10 µM PLP.  Fractions were collected 
following UV reading at 280 nm, and protein was concentrated down to 5 mg/mL using a 
Centricon.  Due to the low concentration of protein, trays were set loading 2:1 
protein/buffer.  Preliminary screening trays were set up utilizing the Hampton I and 
Hampton II screening kits.  Trays were kept at 9 °C. 
 
2nd screening: 
LDC in a 30% glycerol stock was loaded onto a G-25 column and was eluted with 10 
mM malonic acid buffer pH 6.0 in 10 µM PLP.  Fractions were collected following UC 
reading at 280 nm, and protein was concentrated down to 20 mg/mL using a Centricon.  
Preliminary optimization trays were performed by utilizing the Hampton I and Hampton 
II screening kits.  Trays were kept at 9 °C. 
 
Mass Spectroscopy 
 
After collecting S-300 fractions, pure and active fractions of LDC were loaded onto a 9% 
SDS PAGE gel.  After destaining had occurred, gels were slices and digestion of LDC 
was followed by standard protocol (discussed below).  The slices were digested with 
AspN, formic acid, trypsin, and chymotrypsin.  The digested protein was extracted and 
run using a C18-reverse phase LC column (75 micron x 15 cm, Pepmap 300, 5 micron 
particle size). Results showed multiple hit of various strains of LDC, yet LDC from H. 
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Alvei was not the top hit from any of the digestion results.  The following depicts 
fragments found within the published sequence of LDC from H. Alvei: 
Tandem MS/MS for protein modification 
 
Upon sequence alignment, it was seen that the active site lysine exists in a highly 
conserved region of 12 LDC’s from various bacterial strains.  To a sample of pure LDC 
(≈1 nmol in 60 µL), sodium cyanoborohydride (NaCNBH3, 1.0 mg, 16 µmol) was added 
and was incubated at 0 °C for two minutes.  The solution was centrifuged at 10,000 rpm 
for 10 minutes.  The solution was then placed on a 4 kDa Microcon filter and was washed 
4 times with 300 µL 10 mM Potassium Phosphate buffer pH 6.0, containing 10 µM PLP.  
After the final rinse, the solution was resuspended in 150 µL of the washing buffer, and 
was incubated at 25 °C.  After 18 hours, 10 µL of the solution was mixed with 7 µL of 
loading buffer, was denatured at 80 °C for 7 minutes, and was loaded onto a 9% 
acrylamide SDS-PAGE gel.  Bands at approximately 80 kDa were excised and digested 
and run on LC/MS, as described above.      
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